The DEBR Rat Model for Alopecia Areata

Alopecia areata.

n engl j med 367;3 nejm.org july 19, 2012 279 methacin should be used in addition to pancre­ atic stents in high­risk patients. However, post hoc analysis of our trial suggests that indometha­ cin may obviate the need for prophylactic pan­ creatic stent placement (unpublished data), and we therefore agree with Baron et al. that com­ parative effectiveness studies of indomethacin and pancreatic ...

Alopecia areata.

Alopecia areata is a frequent cause of hair loss. The origin of disease is not fully understood. However there are indications for a T-cell mediated autoimmune process. Genetic, immunologic and psychologic factors are important for the outbreak of disease. Most patients show localized patches of acute hair loss, where regrowth is observed spontaneously or with simple topical treatment within fe...

Alopecia Areata

Current Treatments for Alopecia Areata.

Selection of a therapy for a patient with alopecia areata (AA) is frequently based on the age of the patient, disease extent, perhaps disease duration, patient expectations, cost of therapy in terms of time commitment, and financial resources, as well as the results of screening laboratory studies that rule out the presence of other co-morbidities such as anemia, low iron stores, thyroid abnorm...

Th1 Chemokine CXCL10 and Alopecia Areata: The Possible Target for the Treatment of Alopecia Areata

Alopecia areata (AA) is an organ-specific and cell-mediated autoimmune disease. Recent studies have suggested the most important effector cell of AA is NKG2D+CD8+T cells, and outer root sheath (ORS) cells highly express NKG2D ligands, such as MICA, in AA lesions. T lymphocytes densely surround lesional hair bulbs, which is histologically referred to as “swarm of bees”. Immunohistochemical and r...